Skip to main content

Table 2 LBW, preterm delivery, and mean birthweight, by treatment group

From: Sulphadoxine-pyrimethamine plus azithromycin for the prevention of low birthweight in Papua New Guinea: a randomised controlled trial

Outcome ITT analysis   PP analysis  
  Control (SPCQ and placebo) Intervention
(SPAZ)
Risk ratio or ∆ mean (95% CI) P Control (SPCQ and placebo) Intervention
(SPAZ)
Risk ratio or ∆ mean (95% CI) P
LBW (Birthweight < 2,500 g), unadjusted 175/1,008 (17.4) 130/1,013 (12.8) 0.74 (0.60–0.91) 0.005 159/952 (16.7) 122/967 (12.6) 0.76 (0.61–0.94) 0.011
LBW (Birthweight < 2,500 g), adjusteda 0.72 (0.59–0.89) 0.002 0.72 (0.58–0.89) 0.003
Birthweight (g) 2,921.6 2,963.5 41.9 0.049 2,928.7 2,967.9 39.2 0.068
unadjusted [2,890.1–2,953.1] [2,936.0–2,991.0] (0.2–83.6)   [2,986.9–2,960.4] [2,940.3–2,995.4] (−2.8–81.2)  
Birthweight (g) 2,916.6 2,969.0 52.4 0.009 2922.9 2974.1 51.2 0.011
adjustedb [2,888.8–2944.3] [2,941.4–2,996.6] (13.2–91.6)   [2,895.0–2,950.9] [2,946.4–3,001.8] (11.7–90.6)  
PTD (<37 GWs), n (%), unadjusted, best available dating ultrasound 69/652 (10.6) 44/668 (6.6) 0.62 (0.43–0.89) 0.010 63/622 (10.1) 40/651 (6.1) 0.61 (0.41–0.89) 0.009
  1. Data are number (%) or mean [95% CI], unless stated otherwise; ITT, Intention-to-treat; PP, Per-protocol; GW, Gestational weeks; CI, Confidence interval. P <0.05 marked in bold.
  2. aAdjusted for infant gender, gravidity, no. of treatment courses (ITT only), clinic location, season of delivery, bed net use, mid-upper arm circumference, height, maternal highlander heritage.
  3. bAdjusted for infant gender, gravidity, no. of treatment courses (ITT only), clinic location, mid-upper arm circumference, height, maternal highlander heritage.